Susquehanna International Group
BEAM icon

Susquehanna International Group’s Beam Therapeutics BEAM Stock Holding History

Susquehanna International Group’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.62M Sell
134,679
-43,712
-25% -$1.32M ﹤0.01% 4775
2026
Q1 		$4.25M Buy
178,391
+79,880
+81% +$2.22M ﹤0.01% 4544
2025
Q4 		$2.73M Sell
98,511
-26,635
-21% -$680K ﹤0.01% 5050
2025
Q3 		$3.04M Sell
125,146
-462,831
-79% -$9.21M ﹤0.01% 4953
2025
Q2 		$10M Buy
587,977
+395,556
+206% +$6.89M ﹤0.01% 2825
2025
Q1 		$3.76M Buy
192,421
+61,985
+48% +$1.62M ﹤0.01% 4203
2024
Q4 		$3.23M Buy
130,436
+44,789
+52% +$1.14M ﹤0.01% 4339
2024
Q3 		$2.1M Sell
85,647
-80,116
-48% -$2.07M ﹤0.01% 5177
2024
Q2 		$3.88M Buy
165,763
+84,134
+103% +$2.07M ﹤0.01% 3858
2024
Q1 		$2.7M Sell
81,629
-99,110
-55% -$3.09M ﹤0.01% 4713
2023
Q4 		$4.92M Sell
180,739
-191
-0.1% -$4.74K ﹤0.01% 3725
2023
Q3 		$4.35M Buy
180,930
+156,825
+651% +$4.2M ﹤0.01% 3777
2023
Q2 		$770K Sell
24,105
-157,252
-87% -$5.1M ﹤0.01% 7296
2023
Q1 		$5.55M Buy
181,357
+127,212
+235% +$5.02M ﹤0.01% 3302
2022
Q4 		$2.12M Sell
54,145
-14,945
-22% -$669K ﹤0.01% 4589
2022
Q3 		$3.29M Buy
69,090
+5,288
+8% +$302K ﹤0.01% 3892
2022
Q2 		$2.47M Sell
63,802
-8,866
-12% -$352K ﹤0.01% 4455
2022
Q1 		$4.16M Sell
72,668
-22,588
-24% -$1.48M ﹤0.01% 3970
2021
Q4 		$7.59M Buy
95,256
+31,770
+50% +$2.72M ﹤0.01% 3087
2021
Q3 		$5.52M Buy
63,486
+44,868
+241% +$4.51M ﹤0.01% 3770
2021
Q2 		$2.4M Sell
18,618
-8,039
-30% -$641K ﹤0.01% 5503
2021
Q1 		$2.13M Sell
26,657
-41,547
-61% -$3.95M ﹤0.01% 5775
2020
Q4 		$5.57M Buy
+68,204
New +$3.35M ﹤0.01% 3250

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Susquehanna International Group's BEAM Position: Q2 2026 in Review

Susquehanna International Group reduced its Beam Therapeutics (BEAM) stake by 25% in Q2 2026, selling an estimated $1.32M and leaving 134,679 shares worth $4.62M. The position accounts for ﹤0.01% of the portfolio, ranked #4775.

Susquehanna International Group first reported a position in BEAM in Q4 2020 and has held it in 23 quarters since. The position peaked at $10M in Q2 2025. 278 funds tracked by Wall St. Rank hold BEAM as of Q2 2026.

  • Susquehanna International Group held 134,679 shares of Beam Therapeutics worth $4.62M as of Q2 2026.
  • Susquehanna International Group sold 43,712 Beam Therapeutics shares in Q2 2026, an estimated $1.32M.
  • Beam Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q2 2026, its #4775 holding.
  • Susquehanna International Group first reported a position in Beam Therapeutics in Q4 2020 and has held it in 23 quarters since.
  • Susquehanna International Group's Beam Therapeutics position peaked at $10M in Q2 2025.
  • 278 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.